Next Article in Journal
Preparation and Storage of Cryoprecipitate Derived from Amotosalen and UVA-Treated Apheresis Plasma and Assessment of In Vitro Quality Parameters
Previous Article in Journal
Establishing a Herpesvirus Quiescent Infection in Differentiated Human Dorsal Root Ganglion Neuronal Cell Line Mediated by Micro-RNA Overexpression
Previous Article in Special Issue
Understanding COVID-19 Pathogenesis: A Drug-Repurposing Effort to Disrupt Nsp-1 Binding to Export Machinery Receptor Complex
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 11
Issue 7
10.3390/pathogens11070804
Review Report
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Brief Report
Peer-Review Record

Improving Drug Sensitivity of HIV-1 Protease Inhibitors by Restriction of Cellular Efflux System in a Fission Yeast Model

Pathogens 2022, 11(7), 804; https://doi.org/10.3390/pathogens11070804
by Jiantao Zhang 1, Qi Li 1, Shigehiro A. Kawashima 2, Mohamed Nasr 3, Fengtian Xue 4 and Richard Y. Zhao 1,5,6,7,8,*
Reviewer 1:
Jun Wang
Reviewer 2:
Jiayu Liao
Pathogens 2022, 11(7), 804; https://doi.org/10.3390/pathogens11070804
Submission received: 3 July 2022 / Revised: 12 July 2022 / Accepted: 14 July 2022 / Published: 16 July 2022
(This article belongs to the Collection Novel Strategies on Antiviral Drug Discovery Against Human Diseases)

Round 1

Reviewer 1 Report

 

This study aims to solve the long standing problem in the yeast assay which is the drug efflux. Three methods were explored including deletion of the cell walls, electroporation, and inhibition of drug efflux pump. While neither deletion of the cell walls nor electroporation solved the issue, inhibition of drug efflux by the genetically engineered SAK836 strain. The assay was first calibrated using darunavir, and then expanded to other HIV protease inhibitors. All the tested FDA-approved HIV protease inhibitors showed significantly higher drug sensitivities ranging from 0.56 to 2.48 logs in the PR836 strain than in the RE294 strain. Overall, this is an outstanding study and a significant advance in the field. The PR836 strain is expected to speed up the drug discovery process of HIV protease inhibitors. Comments are:

1. This study mainly focuses on genetic deletion of drug efflux pumps, have the authors thought about using drug efflux inhibitors such as CP-100356?

2. Any explanation why the HIV protease inhibitors showed different EC50 fold changes in the yeast assay? Does this mean some drugs are better drug efflux substrates than others?

3. A growth curve comparison of the RE294 and PR836 without HIV PR expression might be useful to demonstrate that genetic modification did not change the growth kinetics. 

4. A comment should be made whether the EC50 values in the yeast assay correlate with their IC50 values in the protease enzymatic assay.  A correlation plot might be useful. It is expected that the yeast assay should be able to rank the potency of HIV protease inhibitors. A negative control with a HCV protease inhibitor might further strengthen the results.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report


Comments for author File: Comments.pdf

Author Response

See the attachment.

Author Response File: Author Response.pdf

Back to TopTop